Corient Private Wealth LP Acquires 184,126 Shares of Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Corient Private Wealth LP acquired 184,126 Xeris Biopharma shares worth approximately $1.46 million, while other institutional investors also increased or initiated positions. Institutional investors and hedge funds now own 42.75% of XERS.
• Analyst sentiment remains mixed: four analysts rate XERS a Buy, two a Hold, and one a Sell. The average price target is $12.80, with recent targets raised to $12–$16.
• XERS opened at $9.10 and has risen above its 50-day and 200-day moving averages, but the company missed its latest EPS estimate despite exceeding revenue expectations. Insiders have sold 224,998 shares worth approximately $1.85 million over the past 90 days.

Corient Private Wealth LP acquired a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 184,126 shares of the company's stock, valued at approximately $1,458,000. Corient Private Wealth LP owned about 0.10% of Xeris Biopharma at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of XERS. Walleye Capital LLC acquired a new stake in Xeris Biopharma in the second quarter valued at approximately $4,841,000. Rice Hall James & Associates LLC bought a new stake in Xeris Biopharma in the first quarter worth approximately $1,456,000. Legal & General Group Plc acquired a new position in shares of Xeris Biopharma during the 2nd quarter worth $15,941,000. Sei Investments Co. increased its stake in shares of Xeris Biopharma by 45.0% during the 1st quarter. Sei Investments Co. now owns 579,210 shares of the company's stock worth $3,359,000 after purchasing an additional 179,863 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Xeris Biopharma by 322.8% during the 1st quarter. Janus Henderson Group PLC now owns 295,489 shares of the company's stock valued at $1,713,000 after purchasing an additional 225,602 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wall Street Zen raised Xeris Biopharma from a "hold" rating to a "buy" rating in a research note on Saturday, September 19th. Weiss Ratings cut Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Leerink Partners increased their price target on Xeris Biopharma from $12.00 to $16.00 and gave the company an "outperform" rating in a report on Thursday, September 10th. Finally, Barclays lifted their price target on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an "overweight" rating in a research report on Thursday, August 20th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Xeris Biopharma presently has an average rating of "Hold" and an average price target of $12.80.

Xeris Biopharma Trading Up 1.7%

XERS stock opened at $9.10 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The business's 50 day moving average is $8.36 and its 200-day moving average is $7.17. Xeris Biopharma Holdings, Inc. has a 1-year low of $5.25 and a 1-year high of $10.08. The firm has a market cap of $1.66 billion, a P/E ratio of -82.73 and a beta of 0.70.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The firm had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Steven Pieper sold 27,600 shares of the business's stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $8.52, for a total value of $235,152.00. Following the completion of the transaction, the insider owned 1,366,053 shares in the company, valued at $11,638,771.56. The trade was a 1.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the company's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total value of $141,494.34. Following the transaction, the insider directly owned 1,127,796 shares in the company, valued at approximately $9,574,988.04. This represents a 1.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 224,998 shares of company stock worth $1,847,219 in the last 90 days. Corporate insiders own 4.35% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc NASDAQ: XERS is a specialty pharmaceutical company focused on developing and commercializing therapies using proprietary formulation and drug-delivery technologies. Its platforms, including XeriSol and XeriJect, are designed to enable liquid or ready-to-use formulations of medicines that may otherwise require refrigeration, reconstitution, or administration by a healthcare professional.

The company's commercial products include Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia; Keveyis (dichlorphenamide), an oral therapy for primary periodic paralysis; and Recorlev (levoketoconazole), an oral treatment for endogenous hypercortisolemia in adults with Cushing's syndrome.

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.